

**BIOLIDICS LIMITED**  
(Company Registration Number: 200913076M)

---

**SIGNING OF NON-BINDING TERM SHEET WITH SYSMEX CORPORATION**

---

The board of directors (the "**Board**") of Biolidics Limited (the "**Company**") is pleased to announce that the Company had, on 20 February 2019, executed a non-binding term sheet (the "**Term Sheet**") with Sysmex Corporation ("**Sysmex**") for collaboration on the development of laboratory assays in the field of circulating tumor cells utilising the Company's ClearCell® FX1 System and Sysmex's molecular imaging flow cytometer MI-FCM (the "**Proposed Collaboration**") in Japan and Singapore, respectively. In addition, the Company and Sysmex will promote laboratory assay developments, applications and market developments for the potential commercialisation of these laboratory assays.

Listed on Tokyo Stock Exchange with a market capital of approximately S\$17 billion as at 18 February 2019, Sysmex delivers total solutions in the domain of healthcare testing, supplying products and services to customers in more than 190 countries. Globally, Sysmex has the number 1 market share in the hematology, hemostasis and urinalysis fields. In 2018, Sysmex registered net sales of ¥281.9 billion with an operating profit of ¥59.0 billion.

**The Company and Sysmex are in the process of negotiation on the terms of the Proposed Collaboration and the definitive agreement(s) to be entered into. Shareholders should note that the Term Sheet is non-binding and that the terms thereof may be subject to further negotiations and changes. There is no certainty or assurance that (i) any definitive agreement will be entered into; or (ii) the Proposed Collaboration will be proceeded with. As such, shareholders and potential investors are advised to exercise caution when dealing or trading in the shares of the Company. Shareholders and potential investors should consult their stockbrokers, bank managers, solicitors or other professional advisers if they have any doubt about the actions they should take.**

The Company will make appropriate announcement(s) when there is further material development regarding the Proposed Collaboration or the Term Sheet in compliance with the relevant provisions of the Listing Manual Section B: Rules of Catalist of the Singapore Exchange Securities Trading Limited.

Save for their respective shareholdings in the Company (if any), none of the Directors or substantial shareholders of the Company has any interest, direct or indirect in the Proposed Collaboration.

**BY ORDER OF THE BOARD**

**Lew Kwang Ping**  
**Chief Executive Officer and Executive Director**  
**20 February 2019**

*This announcement has been prepared by Biolidics Limited (the "**Company**") and its contents have been reviewed by the Company's sponsor, United Overseas Bank Limited (the "**Sponsor**"), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**"). The Sponsor has not independently verified the contents of this announcement.*

*This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

*The contact person for the Sponsor is Mr Chia Beng Kwan, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.*